Independent Prognostic Value of the 67-kd Laminin Receptor in Human Prostate Cancer

Open Access
Publisher Website
Google Scholar
Abstract
Widespread screening for early detection of prostate cancer has resulted in a dramatic rise in the proportion of clinically silent prostate malignant lesions (1–5). To date, no reliable predictors of the risk for such lesions to progress are available. Therefore, the urologist faces the therapeutic dilemma of whether to perform a radical treatment (prostatectomy or external radiotherapy) with the knowledge that some patients will have treatment complications with uncertain survival benefit or to carefully watch this group of patients with the known risk that some will experience the morbidity of clinically overt disease. Furthermore, for many patients, the extent of their prostate carcinoma is underevaluated and unpredictable, which results in inadequate therapeutic strategies (6–9).